
Pneumatic Nebulizers Market
Get a free sample of this report
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.

Request Sectional Data
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Pneumatic Nebulizers Market size exceeded USD 557.7 million in 2020 and is anticipated to grow at over 5.2% CAGR between 2021 and 2027. The rising pervasiveness of asthma and chronic obstructive pulmonary disease will foster the market growth during the forecast timeline. The increasing incidence of respiratory defects is attributable to the growing global air pollution will further fuel the market expansion. Moreover, the growing geriatric population base across the world will spur the market value in the coming years.

The spread of the COVID-19 pandemic across the globe has positively impacted market in 2020. The medical device market witnessed a sudden spike in the sales of pneumatic nebulizers during pandemic. The outbreak of COVID-19 pandemic highlighted the need for aerosol-generating procedures such as nebulizers for the treatment of respiratory disorders and infection such as asthma, SARS-CoV-2 and others. Home-based COVID infected patients used nebulizers to get relief from the symptoms of infection. The demand barbed as the number of infection rate increased and high adoption of home-based treatment.
| Key Takeaway | Details |
|---|---|
| Market Size & Growth | |
| Base Year | 2020 |
| Market Size in 2020 | 557.7 Million (USD) |
| Forecast Period 2021 to 2027 CAGR | 5.2% |
| Market Size in 2027 | 789.9 Million (USD) |
| Key Market Trends | |
| Growth Drivers |
|
| Pitfalls & Challenges |
|
The rising prevalence of asthma and COPD (chronic obstructive pulmonary disease) diseases will propel the industry growth. According to the World Health Organization, in 2019, around 262 million people suffered from asthma and it resulted in 4,61,000 deaths globally. The treatment of asthma and COPD is long-term may result in high healthcare expenditure. Furthermore, rising urbanization, declining quality of air, and high awareness regarding respiratory disease and treatment will further stimulate the demand for pneumatic nebulizers in the industry.
The American Society of Microbiology (ASM) stated that regular use of pneumatic nebulizers at home setting will increase the risks of bacterial infection. The pneumatic nebulizers devices may host the growth of pathogens like Rhizobium, Stenotrophomonas, Staphylococcus, and Streptococcus. This has been negatively impacting the market and will continue to restrain the industry expansion in the coming years. Additionally, lower insurance coverage scenarios in developing economies will further restrict the industry value during the forecast period.

Breath actuated segment was valued at USD 338 million in 2020. The increasing prevalence of asthma, COPD and coronavirus infection in the geriatric population will impel the demand for pneumatic nebulizers products and drive the industry progression. Geriatric population experience various respiratory disorders such as emphysema, chronic obstructive pulmonary disease, asthma, lower respiratory infections and pulmonary hypertension. Treatment of these morbidities require inhaled therapies for that nebulizers are primary required. In addition, rising incidences of respiratory diseases and infection through the world will further boost the demand for pneumatic nebulizers in the industry.

North America pneumatic nebulizers market is expected to showcase over 4.8% growth rate through 2027 led by the growing incidence and prevalence of asthma among the population. According to Asthma and Allergy Foundation of America (AAFA), more than 25 million American people suffer from asthma which equals to one in thirteen American people. The asthma prevalence rate in children is also increasing, around 44.3% of American children (under 18 years old) has asthma. In North America, asthma is more common in adult women than men. The high prevalence of asthma will enhance the demand for aerosol therapy, thereby influencing the industry demand of pneumatic nebulizers over the forecast timeframe.
A few key companies operating in the market are
These market leaders are focusing on numerous strategies such as acquisitions, mergers, partnerships, new product launches, and collaborations to increase their revenue share for pneumatic nebulizers.
Market, By Product
The above information is provided for the following regions and countries:
North America market will witness CAGR of 4.8% through 2027 with increasing product demand impelled by rising prevalence of asthma in the region.
Market size of pneumatic nebulizers had surpassed USD 557.7 million in 2020 and will observe a CAGR of over 5.2% through 2027.
Breath actuated segment was valued at USD 338 million in 2020 on account of increasing prevalence of asthma, COPD and coronavirus infection among geriatric population.
Major players operating in market are Allied Healthcare Products, Inc., Becton, Dickinson and Company, Heyer Medical AG, Philips Respironics, Inc., Salter Labs, TaiDoc Technology, etc.


